Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2101 to 2150 of 3761 results for treatment

  1. Using GP practice lists to identify people at high risk:- What is the clinical and cost effectiveness of using GP practice lists to identify people at high risk of fracture, leading to formal risk assessment and possible treatment?

    high risk of fracture, leading to formal risk assessment and possible treatment? Any explanatory notes(if applicable) Why this is...

  2. Radiofrequency denervation for osteoarthritic knee pain (HTG686)

    Evidence-based recommendations on radiofrequency denervation for osteoarthritic knee pain. This involves applying heat (radiofrequency) energy to damage the nerves (denervation) that are causing pain in the knee.

  3. The STAK tool for preventing and treating knee stiffness (MIB252)

    NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .

  4. Atrial fibrillation: admission rates (stroke, on anticoagulation) (IND38)

    This indicator covers the proportion of patients admitted to hospital for stroke with a pre-existing diagnosis of atrial fibrillation, who were on anticoagulation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG55

  5. Diabetes: T1DM and lipid-lowering therapies (IND277)

    This indicator covers the percentage of patients with type 1 diabetes aged over 40 years (excluding people with a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  6. E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (HTG326)

    Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.

  7. Myocardial infarction: measurement of ejection fraction (IND75)

    This indicator covers the proportion of patients with acute myocardial infarction with measurement of left ventricular ejection fraction before discharge. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG94

  8. Duration of risk of systemic anticancer treatment in people with cancer and COVID-19: Are people who have had SACT recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had SACT less recently?

    NG161/2 Question Duration of risk of systemic anticancer treatment in people with cancer and COVID-19: Are people who have had SACT...

  9. Trauma (QS166)

    This quality standard covers assessing and managing trauma (complex fractures, non-complex fractures, major trauma and spinal injury) in adults, young people and children. It describes high-quality care in priority areas for improvement.

  10. Managing medicines for adults receiving social care in the community (NG67)

    This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.

  11. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  12. Kidney conditions: CKD and eGFR (IND233)

    This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a–G5 (on the register, within the preceding 12 months) who had eGFR measured on at least 2 occasions separated by at least 90 days, and the second test within 90 days before the diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM215.

  13. Pregnancy and neonates: newborn blood spot test communication with 6 weeks of movement in (IND67)

    This indicator covers the proportion of babies with a 'not suspected' result for all the conditions tested for by newborn blood spot testing who have a results letter sent to their parents directly from the child health information service (CHIS) within 6 weeks of notification of movement in. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG86

  14. Cardiovascular disease prevention: lipid lowering therapy for people newly diagnosed with hypertension or T2DM (IND287)

    This indicator covers those patients aged between 25 and 84 years, with a new diagnosis of hypertension or type 2 diabetes recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes), who have a recorded cardiovascular risk assessment score of 10% or more in the preceding 12 months: the percentage who are currently treated with a lipid lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  15. Mortality: cardiovascular disease (IND280)

    This indicator covers under 75 mortality from cardiovascular disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  16. Technology appraisal processes and timelines

    We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the cost comparison appraisal

  17. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date:  15 October 2026

  18. UroShield for preventing catheter-associated urinary tract infections (HTG620)

    Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.

  19. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds (MIB208)

    NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds .

  20. Photodynamic therapy for Barrett's oesophagus (HTG223)

    Evidence-based recommendations on photodynamic therapy for Barrett's oesophagus. This involves using a light-activated drug (called a photosensitising agent) with a laser to destroy the abnormal cells and to promote the growth of healthy cells.

  21. Is a group-based parent training intervention for parents or carers of autistic children and young people clinically and cost effective in reducing early and emerging behaviour that challenges in the short- and medium-term compared with treatment as usual?

    behaviour that challenges in the short- and medium-term compared with treatment as usual? Any explanatory notes(if applicable) Behaviour...

  22. Joint distraction for knee osteoarthritis without alignment correction (HTG381)

    Evidence-based recommendations on joint distraction for knee osteoarthritis without alignment correction. This involves fixing a metal frame around the knee to take weight off the joint and encourage the cartilage to repair itself.

  23. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued Reference number: GID-TA10591

  24. International collaboration

    International collaboration with NICE

  25. About NICE guidelines

    NICE guidelines are evidence-based recommendations for health and care in England and Wales.

  26. What is the role of arm and shoulder specific exercises compared with and/or used as an adjunct to established lymphoedema treatments (such as compression garments and complex decongestive therapy)?

    exercises compared with and/or used as an adjunct to established lymphoedema treatments (such as compression garments and complex...

  27. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

  28. Infections: scoring tools for sore throat (IND323)

    This indicator covers the percentage of diagnoses of sore throat in the preceding 12 months with a recorded FeverPain or Centor score. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  29. Asthma: register (IND186)

    This indicator covers the contractor establishing and maintaining a register of patients with asthma aged 5 or over. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM165

  30. Atrial fibrillation: admission rates (stroke, not on anticoagulation) (IND39)

    This indicator covers the proportion of patients admitted to hospital for stroke with a pre-existing diagnosis of atrial fibrillation, who were not on anticoagulation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG56

  31. Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment (HTG674)

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.

  32. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  33. Diabetes: offered retinal screening (IND69)

    This indicator covers the proportion of eligible people with diabetes who are offered an appointment for diabetic eye screening. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG88

  34. What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:• available tests for diagnosing CAPA• available treatments for CAPA?

    families or carers, on:• available tests for diagnosing CAPA• available treatments for CAPA? Any explanatory notes(if applicable) P:...

  35. Prosthetic intervertebral disc replacement in the cervical spine (HTG217)

    Evidence-based recommendations on prosthetic intervertebral disc replacement in the cervical spine. This involves removing the damaged disc and inserting an artificial disc in its place.

  36. Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) (HTG191)

    Evidence-based recommendations on tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions). This involves cutting the horizontal muscles of the eye (which move the eye from side to side) and reattaching them at the same place.

  37. Laparoscopic nephrolithotomy and pyelolithotomy (HTG137)

    Evidence-based recommendations on laparoscopic nephrolithotomy and pyelolithotomy. This involves inserting a tube through small cuts in the abdomen (keyhole surgery) to remove the kidney stones..

  38. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England

  39. Uterine artery embolisation for fibroids (HTG240)

    Evidence-based recommendations on uterine artery embolisation for fibroids. This involves injecting small particles into the blood vessels that take blood to the uterus, via the groin.

  40. Osteoporosis: register (IND90)

    This indicator covers establishing and maintaining a register of patients aged 50 or over and have not attained the age of 75 with a record of a fragility fracture on or after 1 April 2012 and a diagnosis of osteoporosis confirmed on DXA scan, and patients aged 75 or over with a record of a fragility fracture on or after 1 April 2014 and a diagnosis of osteoporosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM29

  41. Diabetes: did not attend retinal screening (IND68)

    This indicator covers the proportion of eligible people with diabetes who have not attended for diabetic eye screening in the previous 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG87

  42. What is the most clinical and cost-effective strategy, as identified by a consensus survey, for the perioperative management of anticoagulation treatment in people taking a vitamin K antagonist with a target international normalised ratio (INR) of more than 3 who need bridging therapy?

    consensus survey, for the perioperative management of anticoagulation treatment in people taking a vitamin K antagonist with a target...

  43. The health-related quality-of-life evidence of patients with perianal fistulas is also lacking, therefore further research is recommended. Any research should measure the effect of treatment using preference-based measures (such as use of the EQ-5D questionnaire).

    further research is recommended. Any research should measure the effect of treatment using preference-based measures (such as use of the...

  44. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued Reference number: GID-TA10631

  45. Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]

    Discontinued Reference number: GID-TA10329

  46. Superior capsular augmentation for massive rotator cuff tears (HTG477)

    Evidence-based recommendations on superior capsular augmentation for massive rotator cuff tears in adults. This involves using a graft to stabilise the shoulder joint, reduce pain and improve shoulder function.

  47. Diabetes: IFCC-HbA1c 64mmol/mol or less (IND135)

    This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 64 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM96.

  48. Diabetes: excluded from retinal screening (IND71)

    This indicator covers the proportion of eligible people with diabetes who are excluded from diabetic eye screening as they have opted out or are classed as medically unfit. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG90